Abstract FK506-binding protein 2 (FKBP13) is a part of the immunophilin family involved in immunoregulation. It also believed to operate as factor membrane cytoskeletal framework and an ER chaperone. FKBP2 FKBP1 (FKBP12), known immunophilins, are binding proteins for rapamycin FK506, which immunosuppressive drugs. was suggested that immunophilin-like play significant roles regulating intracellu...

Dual Self-Assembly In article number 2203242, Kaihui Nan, Sen Lin, and co-workers, report new multi-hydrophobiccore nanoparticles (MHC-NPs) with high encapsulation capacity for hydrophobic agents. MHC-NPs achieve a maximal tacrolimus (also known as FK506)-loading amount of 18%, which is higher than those previously reported nanocarriers. After being topically administrated, these FK506 exhibit ...

FK506 (Tacrolimus) has the potential to decrease cerebral ischemia-reperfusion injury. However, the clinical trial of FK506 as a neuroprotectant failed due to adverse side effects. This present study aimed to conduct the selective delivery of FK506 to damaged regions, while at the same time reducing the dosage of FK506, by using a liposomal drug delivery system. First, the cytoprotective effect...

The immunosuppressive drug FK506 binds its targets FK506-binding protein (FKBP) family and modulates cellular processes. Recent studies demonstrated that FK506 shows anti-malaria effects. Newly identified FK506-binding protein 35 from Plasmodium falciparum (PfFKBP35) is assumed to be the molecular target of FK506 in the parasite. Currently, molecular and structural basis of growth inhibition of...

We recently reported that the blood concentrations of Tacrolimus (FK506) in rats were markedly increased following the intake of a Chinese herbal preparation, Wuzhi Tablet (WZ, Schisandra sphenanthera extract). In order to identify the underlying mechanisms of the increase in FK506 level, we investigated the effects of WZ on the absorption and first-pass intestinal and hepatic metabolism of FK5...

FK506 (Prograf) is a new immunosuppressive agent, recently approved for use in solid organ transplants. The first use of FK506 was for the indication of refractory liver allograft rejection. This revealed a marked ability to reverse ongoing rejection, even in cases where chronic changes were observed. Between 50 and 70% of patients converted to FK506 had shown improvement. In long-term follow-u...

PURPOSE To investigate the use of topically applied FK506, a new immunosuppressive compound, systemic and ocular absorption was determined in serum and various ocular tissues. METHODS Two drops of 20 microliters FK506 were applied using oil dissolved (OD-FK506) or liposome-bound (LIP-FK506) drug. FK506 concentrations were measured at intervals of 30, 60, and 120 minutes by immunoassay. RESU...

introduction: umbilical cord blood is a rich source of hematopoietic cells and can be used in the clinical setting for hematopoietic cell transplantation in graft versus host disease (gvhd). a number of different drugs have been used as prophylaxis against gvhd including corticosteroids, cyclosporine a (cy a) and fk506. in this study, the in vitro effects of fk506 on cord blood mononuclear cell...

Tacrolimus (FK506) is a hydrophobic immunosuppressive agent that rapidly penetrates the plasmatic membrane and inhibits the signal transduction cascade of T lymphocytes. The objective of this study was the characterization of liposomal FK506 with surfactant-like phospholipids to be administered intratracheally after lung transplantation or in inflammatory lung diseases. We evaluated the optimal...

Tacrolimus (FK506) is a widely used immunosuppressive drug. Its effects on hepatic fibrosis have been controversial and attributed to immunosuppression. We show that in vitro FK506, inhibited synthesis of type I collagen polypeptides, without affecting expression of collagen mRNAs. In vivo, administration of FK506 at a dose of 4 mg/kg completely prevented development of alcohol/carbon tetrachlo...